TRPV1 and Parkinson disease: A study using the selective TRPV1 blocker AMG9810 (10 nmol) for the treatment of PD showed that AMG9810 could attenuate motor deficits in PD rat models after 6-hydroxydopamine (6-OHDA) administration and reduced neuronal death in the substantia nigra pars compacta of PD rat models [79] (Figure 3).